Welcome to the Grand Rounds Further Reading List, Neurology edition, brought to you by the Clinical Library, on Level 4, next to the Auditorium.
This library guide is to help support you in your professional development. Please give us feedback so we can improve this bulletin in the future.
Some sections are under construction and will be ready later in the year. If you are presenting at a later Grand Rounds, please contact email@example.com and tell us about the content of your paper so we can add appropriate resources to the list for when you present your paper.
If you have any questions, please contact the Clinical Library on 9722 8250 or email SWSLHD-BankstownLibrary@health.nsw.gov.au or visit us Monday to Fridays, 8.30am - 5.00pm.
Nelke, C., et al. (2022). "Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients." Journal of Neuroinflammation 19(1): 89 https://doi.org/10.1186/s12974-022-02448-4
Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify factors affecting outcome.
Rodrigues, C. L., et al. (2022). "Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review." Neurological Sciences 43(4): 2271-2276 https://doi.org/10.1007/s10072-021-05823-w
Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that can be exacerbated by many viral infections, including COVID-19. The management of MG exacerbations is challenging in this scenario. We report 8 cases of MG exacerbation or myasthenic crisis associated with COVID-19 and discuss prognosis and treatment based on a literature review.
Vanoli, F. and R. Mantegazza (2022). "Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management." Neurotherapeutics 19(3): 897-910 https://doi.org/10.1007/s13311-022-01181-3
Myasthenia gravis (MG) is a neurological autoimmune disorder characterized by muscle weakness and fatigue. It is a B cell–mediated disease caused by pathogenic antibodies directed against various components of the neuromuscular junction (NMJ). Despite the wide range of adverse effects, current treatment is still based on non-specific immunosuppression, particularly on long-term steroid usage. The increasing knowledge regarding the pathogenic mechanisms of MG has however allowed to create more target-specific therapies. A very attractive therapeutic approach is currently offered by monoclonal antibodies (mAbs), given their ability to specifically and effectively target different immunopathological pathways, such as the complement cascade, B cell–related cluster of differentiation (CD) proteins, and the human neonatal Fc receptor (FcRn). Up to now, eculizumab, a C5-directed mAb, has been approved for the treatment of generalized MG (gMG) and efgartigimod, a FcRn inhibitor, has just been approved by the U.S. Food and Drug Administration for the treatment of anti-acetylcholine receptor (AChR) antibody positive gMG. Other mAbs are currently under investigation with encouraging preliminary results, further enriching the new range of therapeutic possibilities for MG. This review article provides an overview of the present status of mAb-based therapies for MG, which offer an exciting promise for better outcomes by setting the basis of a precision medicine approach.